Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

(2014) A. Kashiwagi et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study

(2014) Takeshi Kadokura et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

(2013) Stephan A. Veltkamp et al.   CLINICAL DRUG INVESTIGATION

The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor

(2013) Wenhui Zhang et al.   CLINICAL DRUG INVESTIGATION

Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2

(2013) Sreeneeranj Kasichayanula et al.   CLINICAL PHARMACOKINETICS

Ipragliflozin Does Not Prolong QTc Interval in Healthy Male and Female Subjects: A Phase I Study

(2013) Wenhui Zhang et al.   CLINICAL THERAPEUTICS

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans

(2013) M. A. Abdul-Ghani et al.   DIABETES

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes

(2013) E. Ferrannini et al.   DIABETES CARE

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus

(2013) Atsunori Kashiwagi et al.   Journal of Diabetes Investigation

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

(2012) Masakazu Imamura et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus

(2012) Stephan A. Veltkamp et al.   CLINICAL THERAPEUTICS

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects

(2012) R. A. Smulders et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study

(2012) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

(2011) Atsuo Tahara et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Global estimates of the prevalence of diabetes for 2010 and 2030

(2009) J.E. Shaw et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL